ANIX

SEC Filing Summary: CopyTele, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended July 31, 1998, for CopyTele, Inc. (Note: The input metadata referenced "Anixa Biosciences," but the filing text explicitly identifies the registrant as CopyTele, Inc.). The company is classified as a Development Stage Enterprise incorporated in November 1982. Its principal activities involve the development and marketing of the MAGICOM(R) 2000, a telephone-based telecommunications product featuring E-Paper(TM) flat panel display technology, and the MAGIC PRINTER. The company also operates a 55% owned joint venture in Shanghai, China (SCE).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: The company reported zero sales for the nine months ended July 31, 1998, consistent with the prior year. Revenue recognition has been deferred pending sustained end-user acceptance.
• Expenses: Selling, general, and administrative expenses increased by approximately $594,000 (12%) compared to the prior nine-month period. This increase was driven by higher employee compensation (hiring marketing and engineering staff), travel costs for dealer meetings, and professional fees related to the Joint Venture and potential SIEC agreement.
• Joint Venture Loss: The company's share of the loss from its Shanghai joint venture (SCE) increased by approximately $57,000 to $301,546, attributed to manufacturing costs over limited production volumes and quality management implementation.
• Interest Income: Decreased by approximately $337,000 due to a significant reduction in average funds available for investment (dropping from a weighted average of $18.6M to $9.5M), despite slightly higher interest rates.
• Inventory: Inventory increased significantly from $131,498 to $1,841,330, reflecting purchases of components for the MAGICOM(R) 2000.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes the company has sufficient funds to maintain current development efforts into the first quarter of fiscal 2000, assuming continued salary waivers by senior executives and collection of amounts due from the Joint Venture. However, no assurance is given that additional funds will be available if needed.
• Strategic Partnership: In July 1998, the company signed an "Agreement in Principle" with Shanghai Instrumentation and Electronics Holding Group Company (SIEC). This proposes a cross-investment where CopyTele would issue ~11.5 million shares (approx. 20% ownership) to SIEC in exchange for a ~20% interest in SIEC. This is subject to final agreements and governmental approvals.
• Risks: Key risks include the inability to generate significant revenue, the success of the Joint Venture in producing MAGICOM(R) 2000, foreign currency volatility, and the potential for competitive products to render the company's technology obsolete.
• Stock-Based Compensation: The company recorded a non-cash expense of $255,000 for stock options granted to consultants. Pro forma net loss would have been higher ($8.2M) if employee stock options were valued under SFAS No. 123.

Investor Verification Checklist

• Verify the status of the "Agreement in Principle" with SIEC and the likelihood of closing the cross-investment deal.
• Confirm the timeline for the collection of the $4.65 million receivable from the Shanghai Joint Venture (SCE).
• Assess the progress of MAGICOM(R) 2000 sales to end-users to determine when revenue recognition can begin.
• Review the burn rate relative to the $6.1 million cash balance to validate the runway into fiscal 2000.
• Monitor the financial health of the Shanghai Joint Venture, which has incurred cumulative losses of $1.46 million since inception.